Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
about
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingUsefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatmentAdvanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upEvaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinomaEarly Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
P2860
Q26783895-4B331B41-D0D2-46AD-9502-2F2061124F68Q26799914-BFEA89E1-FB70-493C-B367-40A1AA99B3C8Q26851033-D182B725-0EBC-4E78-B316-083C10F5586BQ30365378-86C93BC0-E513-4633-B6A9-1D194DA1FFBFQ35092567-A54F7136-A6A4-4C92-B647-75740646DB09Q35793100-98E898D9-BCF2-4187-B104-B4BA3C722C40Q37513083-F57EDE3D-3E49-4A3B-A4D0-3FD165F10DA2Q38676421-27CA9FBD-23AD-4A27-B725-026D2FCDF82EQ39030388-5C739286-10B4-4D2D-8B48-F751302E4249Q39473421-F5BE49C9-30ED-4B66-9580-3C7575B0D42CQ48018285-2ED9C181-D035-4F1A-B912-4FFC218EB123Q48368428-DD08DE0E-9BAF-491E-8A1A-0FB5C0B81466Q57067866-B7F7EF43-C6D7-4917-81AB-F4004ED5716C
P2860
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@ast
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@nl
type
label
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@ast
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@nl
prefLabel
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@ast
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@nl
P2093
P2860
P356
P1433
P1476
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
P2093
Fuminori Moriyasu
Katsutoshi Sugimoto
Kazuhiro Saito
Naohisa Kamiyama
Nicolas Rognin
Yasuharu Imai
Yoshihiro Furuichi
P2860
P304
P356
10.1111/LIV.12098
P577
2013-01-11T00:00:00Z